SRC and cancer: Moreover, we also identified the C1/C2‐subtype‐like liver cancer cell lines from cancer cell line encyclopedia (CCLE, see also Supporting Methods, Supporting Information) and examined which drugs can generate significant different effects between the two subtypes, and we observed that the C1‐like liver cancer cell lines were more sensitive to a SRC inhibitor saracatinib (also known as AZD0530) than the C2‐like cell lines (Figure 6e).